Compass Therapeutics Short-Term Investments

The latest short-term investments for CMPX is $140M as of June 2026. That compares with $78M in the prior-year period — up 84.9% year over year. Investors often review this figure alongside Compass Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CMPX's short-term investments moved from $78M to $140M — a 84.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Compass Therapeutics's operating scale or balance-sheet position.

A short-term investments figure of $140M for CMPX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CMPX's short-term investments ($140M), review year-over-year change from $78M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Compass Therapeutics's short-term investments against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.